ID   HuO9
AC   CVCL_1298
SY   Huo9; HUO9; Hu09
DR   CLO; CLO_0009875
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03471626
DR   cancercelllines; CVCL_1298
DR   Cell_Model_Passport; SIDM00599
DR   ChEMBL-Cells; CHEMBL3308748
DR   ChEMBL-Targets; CHEMBL1075476
DR   Cosmic; 907072
DR   Cosmic; 931040
DR   Cosmic-CLP; 907072
DR   DepMap; ACH-001526
DR   EGA; EGAS00001000978
DR   GDSC; 907072
DR   GEO; GSM320823
DR   GEO; GSM1669921
DR   GEO; GSM1676303
DR   GEO; GSM1701638
DR   GEO; GSM1914988
DR   GEO; GSM1914989
DR   GEO; GSM1914990
DR   GEO; GSM1914991
DR   IARC_TP53; 21390
DR   JCRB; JCRB0427
DR   LINCS_LDP; LCL-1423
DR   PharmacoDB; HuO9_643_2019
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_1298
DR   Wikidata; Q54896887
RX   DOI=10.11418/jtca1981.16.3_173;
RX   PubMed=2170070;
RX   PubMed=2691514;
RX   PubMed=9359923;
RX   PubMed=12405284;
RX   PubMed=14669798;
RX   PubMed=15289353;
RX   PubMed=20164919;
RX   PubMed=26320182;
RX   PubMed=26351324;
RX   PubMed=27397505;
RX   PubMed=29334376;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Characteristics: Established from a xenograft established in athymic nude mice after five passages.
CC   Doubling time: 57 hours (PubMed=2170070); 43.3 hours (PubMed=14669798).
CC   HLA typing: A*24:01,33:03; B*44:03:01,51:01; C*14:02,14:03 (PubMed=15289353).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=9359923).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: H3K4me1 ChIP-seq epigenome analysis.
CC   Omics: H3K27ac ChIP-seq epigenome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=2.89%; Native American=0%; East Asian, North=77.77%; East Asian, South=13.74%; South Asian=0%; European, North=1.78%; European, South=3.83% (PubMed=30894373).
CC   Derived from site: In situ; Bone, right distal femur; UBERON=UBERON_0004406.
ST   Source(s): Cosmic-CLP=907072; DepMap=ACH-001526; JCRB=JCRB0427
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 11
ST   D16S539: 11
ST   D18S51: 13
ST   D21S11: 28
ST   D3S1358: 16
ST   D5S818: 13
ST   D7S820: 10
ST   D8S1179: 15
ST   FGA: 24
ST   Penta D: 11,13
ST   Penta E: 17,21
ST   TH01: 9
ST   TPOX: 9
ST   vWA: 14
DI   NCIt; C9145; Osteosarcoma
DI   ORDO; Orphanet_668; Osteosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_2958 ! HuO9N2
SX   Female
AG   13Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 39
//
RX   DOI=10.11418/jtca1981.16.3_173;
RA   Mihara K., Miyazaki M., Fushimi K., Tsuji T., Inoue Y., Fukaya K.-i.,
RA   Ohashi R., Namba M.;
RT   "The p53 gene status and other cellular characteristics of human cell
RT   lines maintained in our laboratory.";
RL   Tissue Cult. Res. Commun. 16:173-178(1997).
//
RX   PubMed=2170070; DOI=10.1097/00003086-199010000-00036;
RA   Kawai A.;
RT   "A newly established human osteosarcoma cell line with osteoblastic
RT   properties.";
RL   Clin. Orthop. Relat. Res. 259:256-267(1990).
//
RX   PubMed=2691514; DOI=10.1007/BF00391353;
RA   Kawai A., Ozaki T., Ikeda S., Oda T., Miyazaki M., Sato J., Taketa K.,
RA   Inoue H.;
RT   "Two distinct cell lines derived from a human osteosarcoma.";
RL   J. Cancer Res. Clin. Oncol. 115:531-536(1989).
//
RX   PubMed=9359923; DOI=10.18926/AMO/30789;
RA   Mihara K., Miyazaki M., Kondo T., Fushimi K., Tsuji T., Inoue Y.,
RA   Fukaya K.-i., Ishioka C., Namba M.;
RT   "Yeast functional assay of the p53 gene status in human cell lines
RT   maintained in our laboratory.";
RL   Acta Med. Okayama 51:261-265(1997).
//
RX   PubMed=12405284; DOI=10.1023/A:1020395816633;
RA   Kimura K., Nakano T., Park Y.-B., Tani M., Tsuda H., Beppu Y.,
RA   Moriya H., Yokota J.;
RT   "Establishment of human osteosarcoma cell lines with high metastatic
RT   potential to lungs and their utilities for therapeutic studies on
RT   metastatic osteosarcoma.";
RL   Clin. Exp. Metastasis 19:477-485(2002).
//
RX   PubMed=14669798; DOI=10.1023/A:1027355610603;
RA   Nakano T., Tani M., Ishibashi Y., Kimura K., Park Y.-B., Imaizumi N.,
RA   Tsuda H., Aoyagi K., Sasaki H., Ohwada S., Yokota J.;
RT   "Biological properties and gene expression associated with metastatic
RT   potential of human osteosarcoma.";
RL   Clin. Exp. Metastasis 20:665-674(2003).
//
RX   PubMed=15289353; DOI=10.1158/0008-5472.CAN-04-0522;
RA   Tsukahara T., Nabeta Y., Kawaguchi S., Ikeda H., Sato Y.,
RA   Shimozawa K., Ida K., Asanuma H., Hirohashi Y., Torigoe T., Hiraga H.,
RA   Nagoya S., Wada T., Yamashita T., Sato N.;
RT   "Identification of human autologous cytotoxic T-lymphocyte-defined
RT   osteosarcoma gene that encodes a transcriptional regulator,
RT   papillomavirus binding factor.";
RL   Cancer Res. 64:5442-5448(2004).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=26320182; DOI=10.18632/oncotarget.5177;
RA   Ren L., Mendoza A., Zhu J., Briggs J.W., Halsey C., Hong E.S.,
RA   Burkett S.S., Morrow J.J., Lizardo M.M., Osborne T., Li S.Q.,
RA   Luu H.H., Meltzer P.S., Khanna C.;
RT   "Characterization of the metastatic phenotype of a panel of
RT   established osteosarcoma cells.";
RL   Oncotarget 6:29469-29481(2015).
//
RX   PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074;
RA   Teicher B.A., Polley E.C., Kunkel M., Evans D., Silvers T.E.,
RA   Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J.,
RA   Harris E., Monks A., Morris J.;
RT   "Sarcoma cell line screen of oncology drugs and investigational agents
RT   identifies patterns associated with gene and microRNA expression.";
RL   Mol. Cancer Ther. 14:2452-2462(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=29334376; DOI=10.1038/nm.4475;
RA   Morrow J.J., Bayles I., Funnell A.P.W., Miller T.E., Saiakhova A.,
RA   Lizardo M.M., Bartels C.F., Kapteijn M.Y., Hung S., Mendoza A.,
RA   Dhillon G., Chee D.R., Myers J.T., Allen F., Gambarotti M., Righi A.,
RA   DiFeo A., Rubin B.P., Huang A.Y., Meltzer P.S., Helman L.J., Picci P.,
RA   Versteeg H., Stamatoyannopoulos J.A., Khanna C., Scacheri P.C.;
RT   "Positively selected enhancer elements endow osteosarcoma cells with
RT   metastatic competence.";
RL   Nat. Med. 24:176-185(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//